Yes, so, thank you, Toshiya, a lot of good questions. I mean, let's start with the 2022 guidance. I think you already addressed most of the salient points here. So, we expect strong chip demand, and our outlook for the full-year is indeed calling out better industry conditions. Originally, we were planning on an industry growth of 10%. We are increasing that to about 12% and it's a reflection on wafer starts growing at about 8%, and the overall CapEx -- industry CapEx growing at about around 20%. We are encouraged by the strong execution of our customers, and the fact that many of the node transitions are expected to be largely on schedule. And this is obviously a very important consideration for us, because you know of the great opportunity per wafer that we have in new device architectures, and that's really the primary driver for the strong outperformance that we expect to deliver this year. We expect the organic outperformance to be about five to seven points. And that's going to be offsetting the decline we expect to see in our Aramus bag. As we've said all along, we were expecting some level of contraction in the COVID-related opportunities; we just didn't know when that will happen. I think we have the answer to that question, and it's [currently] [Ph] is happening a little bit faster than we thought. So, we expect the Aramus bag to be modestly down versus last year, so it's going to be a little bit of a headwind. And the last point for the full-year guidance is the very strong performance of the acquisition that we made last year, the Precision Microchemicals, which we expect will deliver about a bit short of one point of growth to the top line. So, if you wrap it all up you get to that 18% to 20% growth rate for the year. In terms of the supply question, we are supply-constrained, like everybody else in this space. I think that the supply constraints impact all three divisions in various ways. We have made a lot of progress. I mean, labor is no longer really a challenge. I think we've been able to staff all of our shifts in all of our major sites very adequately. But we are still facing a number of lingering supply challenges. The team has done a tremendous job managing these situations and finding solutions, and that's actually why we are able to commit to this very exciting annual guidance. But those supply chain issues remain. And then, finally, on your question about China, it is a developing situation. We saw a little bit of an impact in Q1. We expect that impact to be a little bit more significant going into Q2, and that's certainly something that we have taken into account in our Q2 guidance.